Identification of Active Compounds Sample Clauses

Identification of Active Compounds. During the Research Term, the parties shall collaborate in accordance with the Research Plan to perform research to identify Active Compounds with the potential to become Allergan Designated Compounds or ACADIA Designated Compounds. The parties shall report the results of such research promptly to the RMC.
Sample 1Sample 2
AutoNDA by SimpleDocs
Identification of Active Compounds. Promptly after completing the screening of a batch of compounds under this Section 5.1 in the appropriate assays, the Parties will provide to the Research Management Committee the results of such screening. The Research Management Committee will review such results promptly after receipt and will determine which of the screened compounds meet the requirements established by the Research Management Committee for identification as Active Compounds. Upon identifying Active Compounds, the Research Management Committee shall add such compounds to the list of all Active Compounds, which shall be maintained by the Research Management Committee, and shall forward the updated list to each Party.
Sample 1Sample 2
Identification of Active Compounds. Promptly after completing the testing of a batch of compounds under this Section 4.1 in the Assays, ACADIA will provide to the RMC the results of such testing. The RMC will review such Assay results promptly after receipt and will determine which of the screened compounds meet the requirements established in the Research Plan for designation as Active Compounds, as such requirements may be modified by the RMC. Upon designating Active Compounds, the RMC shall add such compounds to the list of all Active Compounds, which shall be maintained by the RMC, and shall forward the updated list to each party.
Sample 1
Identification of Active Compounds. Initially, ArQule will not identify the structures of the individual ArQule Compounds. Searxx xxx screen the ArQule Compounds against any Targets within the Field during the term of this Agreement. If Searxx xxxects any Active Compound, Searxx xxxll disclose to ArQule the location of the Active Compound in the Compass Array Library or Mapping Array, and ArQule shall determine whether such Active Compound is an Available Compound as soon as reasonably practicable, but no later than [*] after such request if the request is for not more than [*] ArQule Compounds within any period of [*]. During the period in which ArQule determines whether an ArQule Compound is an Available Compound, ArQule shall tentatively reserve for Searxx xx an exclusive basis such ArQule --------------- *Confidential treatment has been requested for the marked portion.
Sample 1
Identification of Active Compounds. Promptly after completing the screening of a batch of compounds under this Section 4.2 in the appropriate Target Assays, SUGEN will provide to the RMC the results of such screening. The RMC will review such Target Assay results promptly after receipt and will determine which of the screened compounds meet the requirements established by the RMC for identification as Active Compounds. Upon identifying Active Compounds, the RMC shall add such compounds to the list of all Active Compounds, which shall be maintained by the RMC, and shall forward the updated list to each party. SUGEN will promptly provide to the RMC any information in SUGEN's possession regarding the chemical structure and properties of Active Compounds.
Sample 1
Identification of Active Compounds. ArQule hereby grants Cubist a nonexclusive, worldwide license (without the right to sublicense) under, the ArQule Patent Rights and other rights in ArQule Technology to screen the delivered Mapping Array compounds against any Targets in the Field. Cubist agrees to screen the delivered Mapping Array compounds expeditiously and in a scientifically sound manner. Cubist shall promptly disclose to ArQule the array plate number and well number of any Active Compounds. ArQule will promptly determine whether the Active Compounds are Available Compounds and notify Cubist of such determination. If an Active Compound is not an Available Compound, Cubist shall have no rights with respect to that Active Compound. For Available Active Compounds, ArQule shall disclose to Cubist the chemical composition and structure of those Active Compounds, and Cubist shall disclose to ArQule the identity of the Target, level of activity, and a description of the primary assays used to detect the activity. All such information disclosed by ArQule and Cubist shall be deemed Confidential Information and, as such, is subject to the restrictions set forth in Article 6.
Sample 1
Identification of Active Compounds. Initially, ArQule will not identify the structures of the individual ArQule Compounds. Monsanto may screen the ArQule Compounds against any Targets within the Field during the term of this Agreement. If Monsanto detects any Active Compound, Monsanto shall disclose to ArQule the location of the Active Compound in the Compass Array Library or Mapping Array, and ArQule shall determine whether such Active Compound is an Available Compound as soon as reasonably practicable, but no later than [*] after such request if the request is for not more than [*] ArQule Compounds within any period of [*]. During the period in which ArQule determines whether an ArQule Compound is an Available Compound, ArQule shall tentatively reserve for Monsanto on an exclusive basis such ArQule Compound pending its determination. If an Active Compound is not an Available Compound, then ArQule shall not disclose the structure of such Active Compound and such Active Compound may not be designated as a Licensed Compound under this Agreement. If an Active Compound is an Available Compound, then subject to confirmation of significant functional activity by the Research Committee (which confirmation will occur as soon as reasonably practicable but not more than [*] after Monsanto furnishes the confirmatory data to the Research Committee), ArQule will disclose (i) the full structure of the Active Compound correlated to the well location, (ii) [*] and (iii) if the Active Compound is identified in a Mapping Array, the structures, but not the locations in the Mapping Array, of the inactive ArQule Compounds that Monsanto has screened from the same Mapping Array, and ArQule shall reserve to Monsanto the Active Compound and up to [*] Active Homologs that are Available Compounds. All such disclosed information shall be treated as Confidential Information by the Receiving Party. ArQule shall furnish Monsanto with up to [*] resynthesized Active Compounds per month in quantities of not less than [*], as directed by the Research Committee, [*] and additional resynthesized Active Compounds in quantities of not less than [*], as directed by the Research Committee, at a cost of [*]. ArQule shall maintain the compound reservation for a period of [*] after Monsanto receives the resynthesized Active Compound. Monsanto may extend the [*] reservation period for not more than [*] Active Compounds at the same time, subject to increase by the Research Committee. Monsanto may subsequently request that the Research ...
Sample 1
AutoNDA by SimpleDocs
Identification of Active Compounds. Each Party will inform the other Party's members on the JRC in writing as promptly as practicable upon the Party's discovery, synthesis, acquisition or identification of Active Compounds during the Research Term and (in the case of Axys) during the license period set forth in Section 3.1(a)(ii). The notifying Party will include in such notices the structure of such Active Compounds and the assay information showing the required functional criteria as provided in Section 1.1(a).
Sample 1
Identification of Active Compounds 
Sample 1

Related to Identification of Active Compounds

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Research Collaboration (a) GSK hereby grants to Anacor a non-exclusive, non-royalty bearing license under the GSK IP, solely as and to the extent necessary or important to conduct activities for which Anacor is responsible under the Research Plans during the Research Collaboration Term.

  • Joint Patents Neither Party shall have any obligation to file or prosecute any Joint Patent. To the extent a Party wishes to prosecute a Joint Patent, the Parties will mutually agree upon which Party will have the first right to prosecute such Joint Patent, based on the contribution of each Party to such invention and each Party’s potential interest in products based upon such invention. If the Party having such first right does not wish to prosecute such Joint Patent, it shall inform the other Party promptly, but in any event no later than [***] after the Parties have agreed upon which Party had the first right to prosecute such Joint Patent. If the Party having such first right does not wish to prosecute such Joint Patent, the other Party may, upon written notice to such Party, prosecute such Joint Patent. The Party that prosecutes a Joint Patent pursuant to this Section 5.2(b) (the “prosecuting Party”) will solely bear its own internal costs for such prosecution and will solely bear the external costs for such prosecution (e.g., outside counsel, filing fees, etc.). Licensee will have the first right, but not the obligation, to prosecute infringement of any Joint Patents that is related to the Exclusively Licensed Know-How or a product competitive, or potentially competitive, with a Licensed Product; and Licensor will have the first right, but not the obligation, to prosecute infringement of any Joint Patents in all other cases. The Parties shall first confer and mutually agree regarding any such prosecution of infringement; provided, however, that Licensee shall have the right, without the consent of Licensor, to assert a Joint Patent against a Third Party in a defense of or counterclaim to any claim or assertion of infringement of a Patent or misappropriation of Know-How Controlled by such Third Party.

  • Product Testing Upon request, Customer shall provide Operator a laboratory report for each Product delivery by Customer or Customer’s supplier. Operator will not be obligated to receive Contaminated Product for throughput through the Pipelines, nor will Operator be obligated to accept Product that fails to meet the applicable quality specifications for the Berths under the BAUTA and any Terminal Service Orders issued thereunder.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Research Plans The Research Plan for the [***] Designated Target is attached as Schedule 2.2.3-1. Subsequent Research Plans agreed upon in accordance with Section 2.4.2.4 will be attached as additional sequentially numbered schedules (Schedule 2.2.3-2, Schedule 2.2.3-3, etc.).

  • Joint Patent Rights If not already established under the Research Collaboration Agreement, prior to either Party filing any Patent Right disclosing Joint Program Technology or Joint TAP Platform Improvements, the Parties shall establish a patent committee (the “Patent Committee”) comprised of at least one (1) representative of each Party for the purpose of facilitating the preparation, filing, prosecution, maintenance and defense of Joint Patent Rights. As agreed upon by the Parties, meetings of the Patent Committee may be face-to-face or may be conducted by teleconferences or videoconferences, from time to time as needed. The Patent Committee will be the forum through which the Parties coordinate their respective obligations to each other described in Sections 5.2.2 and 5.2.3 hereof and in this Section. In the event the Parties conceive or generate any Joint Program [***] Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Confidential Treatment Requested by CytomX Therapeutics, Inc. Technology or Joint TAP Platform Improvements, the Parties shall promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon, which Party will control filing, prosecution and maintenance of such patents and how to pay for the filing, prosecution and maintenance of such patents. It is presumed that CytomX will control filing, prosecution and maintenance of Joint Patent Rights claiming Joint Program Technology or Joint Unconjugated Probody Platform Improvements, and that ImmunoGen will control filing, prosecution and maintenance of Joint Patent Rights claiming Joint TAP Platform Improvements or Joint Conjugation Probody Platform Improvements. Neither Party will file any Joint Patent Right without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. The Party controlling filing and prosecution of any such Joint Patent Right (a) shall keep the other Party informed regarding each Patent Right, (b) shall consider in good faith any recommendations made by the other Party in regard to the filing, prosecution or maintenance of any such Patent Right and (c) shall not unreasonably refuse to incorporate any recommendations made by the other Party in regard to such filing, prosecution or maintenance.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!